Drug News

Why Pfizer Was Prohibited From Subsidizing Its Heart Drugs

A district judge ruled that Pfizer cannot directly or indirectly pay out-of-pocket costs for Medicare patients to receive its heart drugs Vyndaqel and Vyndamax, which cost $225,000 annually.

The judge ruled in favor of HHS, saying that allowing Pfizer to run programs that reimburse patients for drugs would violate federal kickback law.

“Because the stated intent of the payments Pfizer proposes here are to increase the number of Medicare beneficiaries who purchase the drug, the court is unable to issue the declaratory judgment Pfizer seeks or to issue judgment in its favor,” Judge Mary Kay Vyskocil wrote.

The case was watched closely among drugmakers, as its ruling means they still cannot pay co-pays for patients enrolled in government-run insurance plans.


Dr. Oche Otorkpa PG Cert, MPH, PhD

Dr. Oche is a seasoned Public Health specialist who holds a post graduate certificate in Pharmacology and Therapeutics, an MPH, and a PhD both from Texila American University. He is a member of the International Society of Substance Use Professionals and a Fellow of the Royal Society for Public Health in the UK. He authored two books: "The Unseen Terrorist," published by AuthorHouse UK, and "The Night Before I Killed Addiction."
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker